BEIJING - AstraZeneca is expanding its main pharmaceutical manufacturing facility and logistics center in China even as the company prepares to close some smaller sites in Spain, Belgium and Sweden, according to AstraZeneca executives in the United Kingdom and China
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
Pharmaceutical industry organizations offered alternatives to tariffs that could maintain a secure domestic supply chain in public comments filed in response to a 232 investigation.
The US FDA has ordered compounders of the Danish firm's obesity drug semaglutide to shut up shop later this month, but competition from Eli Lilly is only increasing.
The weak US dollar helped some companies reporting first-quarter results and hindered others reporting in stronger currencies. But even the impacts of currencies and Medicare modernization on first-quarter revenues were overlooked when an end to the trade wars seemed possible.
